Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iparomlimab and Tuvonralimab (QL1706) Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer: A Single-Arm Phase II Clinical Trial

NCT06986057 is registered in ClinicalTrials.gov with Shandong Tumor Hospital as lead sponsor.

NCT NCT06986057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06986057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iparomlimab and Tuvonralimab (QL1706) Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer: A Single-Arm Phase II Clinical Trial
Lead sponsor
Shandong Tumor Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2025
Completion date
December 31, 2026
Enrollment
28 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, neoadjuvant therapy